Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6211592 | 0.89 | LMNA (0.52) | LMNASMN1; SMN2SOAT1 | |
| SCHEMBL6273235 | 0.88 | LMNA (0.71) | LMNASMN1; SMN2SOAT1 | |
| SCHEMBL6276242 | 0.88 | LMNA (0.71) | LMNASMN1; SMN2SOAT1 | |
| SCHEMBL6273825 | 0.88 | LMNA (0.71) | LMNASMN1; SMN2SOAT1 | |
| SCHEMBL6275012 | 0.88 | LMNA (0.71) | LMNASMN1; SMN2SOAT1 | |
| SCHEMBL6780908 | 0.88 | LMNA (0.71) | LMNASMN1; SMN2SOAT1 | |
| SCHEMBL6268668 | 0.88 | LMNA (0.71) | LMNASMN1; SMN2SOAT1 | |
| SCHEMBL6215986 | 0.88 | SOAT1 (0.56) | SOAT1 | |
| SCHEMBL6268678 | 0.87 | LMNA (0.72) | LMNASMN1; SMN2SOAT1 | |
| SCHEMBL6270942 | 0.85 | LMNA (0.75) | LMNASMN1; SMN2SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020451-B1 | ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-6797717-B2 | ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS | KOWA COMPANY, LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20030087928-A1 | Novel anilide compounds and drugs containing the same | KOWA COMPANY, LTD., JAPAN | 2003-05-08 | — | — | US | disclosed |
| US-20020099074-A1 | Novel anilide compounds and drugs containing the same | KOWA COMPANY, LTD.,JAPAN | 2002-07-25 | — | — | US | disclosed |
| US-6362208-B1 | ANTICHOLESTEROL AGENT | KOWA COMPANY, LTD. (JP) | 2002-03-26 | — | — | US | disclosed |
| EP-1020451-A1 | NOVEL ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087928-A1 | Novel anilide compounds and drugs containing the same | ACAT1, ACAT2, LCAT | LMNA 4625/4885SMN1; SMN2 4514/4885SOAT1 4/4885 |
| US-20020099074-A1 | Novel anilide compounds and drugs containing the same | SOAT1, SOAT2, LCAT | LMNA 4682/4885SMN1; SMN2 2945/4885SOAT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.